Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Braintree Laboratories |
---|---|
Information provided by: | Braintree Laboratories |
ClinicalTrials.gov Identifier: | NCT00153127 |
The purpose of this study is to assess treatment responses comparing a newly FDA-approved PEG laxative versus placebo.
Condition | Intervention | Phase |
---|---|---|
Constipation |
Drug: polyethyleneglycol3350 |
Phase IV |
Study Type: | Interventional |
Study Design: | Randomized, Double-Blind, Placebo Control, Parallel Assignment |
Official Title: | Comparison of Braintree PolyethyleneGlycol(PEG) Laxative and Placebo for Relief of Constipation From Constipating Medications |
Estimated Enrollment: | 100 |
Study Start Date: | November 2001 |
Ages Eligible for Study: | 19 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
United States, Alabama | |
Mobile, Alabama, United States, 36693 | |
United States, Florida | |
St. Petersburg, Florida, United States, 33707 | |
United States, Missouri | |
St. Louis, Missouri, United States, 63141 | |
United States, North Carolina | |
Raleigh, North Carolina, United States, 27612 |
Principal Investigator: | Jorge Herrera, MD | University of South Alabama |
Study ID Numbers: | 851-17 |
Study First Received: | September 7, 2005 |
Last Updated: | September 7, 2005 |
ClinicalTrials.gov Identifier: | NCT00153127 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Signs and Symptoms Laxatives Signs and Symptoms, Digestive Constipation Cathartics |
Signs and Symptoms Signs and Symptoms, Digestive Constipation |